唑来膦酸、地舒单抗或特立帕肽对2型糖尿病患者骨微结构的中期影响:一项预试验
这项72周随机开放标签盲法终点预试验纳入129例高骨折风险的绝经后2型糖尿病女性,比较唑来膦酸、地舒单抗、特立帕肽与标准治疗对骨微结构的影响。24周中期分析显示特立帕肽早期改善骨微结构,地舒单抗 modest 增加胫骨硬度,需要更大样本研究验证。
要点
- 特立帕肽早期改善2型糖尿病绝经后女性胫骨和桡骨骨微结构。
- 地舒单抗 modest 增加胫骨刚度,唑来膦酸仅改善胫骨总vBMD。
- 抗骨吸收药降低骨转换标志物,特立帕肽升高并出现合成窗口。
核心结论
- 特立帕肽在2型糖尿病绝经后女性中显示骨微结构早期改善,地舒单抗 modest 增加胫骨远端刚度。
- 需要更大样本研究明确合成与抗骨吸收治疗在该人群中的相对效应。
研究设计与样本
- 72周随机、开放标签、盲法终点(PROBE)预试验,单中心,印度。
- 纳入129例2型糖尿病病程超过5年且高骨折风险的绝经后女性。
- 按1:1:1:1随机分配至唑来膦酸5 mg每年、地舒单抗60 mg每6个月、特立帕肽20 µg每日或仅标准治疗(钙/胆钙化醇)72周。
- 预设24周中期探索性分析,采用第二代高分辨率外周定量CT评估胫骨远端和桡骨骨微结构及骨转换标志物。
主要发现
- 特立帕肽显著改善胫骨和桡骨的总及小梁 volumetric BMD(vBMD)、小梁数目(Tb.N)、胫骨小梁骨体积分数(BV/TV)及桡骨小梁厚度(Tb.Th)。
- 地舒单抗改善胫骨小梁vBMD和Tb.N。
- 唑来膦酸仅改善胫骨总vBMD。
- 微有限元分析衍生强度参数除地舒单抗 modest 增加胫骨刚度外无变化。
- 骨转换标志物在抗骨吸收药中降低、特立帕肽中升高,6周时显示合成窗口。
临床怎么用
- 对高骨折风险的绝经后2型糖尿病女性,特立帕肽可能早期改善骨微结构。
- 地舒单抗可能 modest 增加胫骨刚度,唑来膦酸对骨微结构影响有限。
- 骨转换标志物变化可辅助监测治疗反应,6周时特立帕肽显示合成窗口。
局限性
- 预试验样本量小,需更大规模 adequately powered 研究验证。
- 24周中期探索性分析,非最终结论。
- 开放标签设计,仅终点盲法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Type 2 diabetes (T2D) increases fragility fracture risk despite normal/elevated areal bone mineral density (aBMD), attributed to compromised bone microarchitecture. However, evidence guiding pharmacologic management of diabetic bone disease remains limited. OBJECTIVE: We aimed to evaluate interim effects of zoledronate, denosumab, or teriparatide on bone microarchitecture in postmenopausal women with T2D at high fracture risk. METHODS: A 72-week, randomized, open-label, blinded-end point (PROBE) pilot clinical trial (CTRI/2022/02/039978) was conducted at a single tertiary care center in India. Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < -2.5 [corrected for T2D] with elevated FRAX®). Participants were randomly assigned in a 1:1:1:1 ratio to receive zoledronate 5 mg annually, denosumab 60 mg every 6 months, teriparatide 20 µg daily, or only standard of care (calcium/cholecalciferol) for 72 weeks. The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius. Bone turnover markers (BTMs) were also evaluated. RESULTS: Baseline demographic, biochemical, aBMD, and HR-pQCT parameters were comparable across groups. Teriparatide significantly improved total and trabecular volumetric BMD (vBMD) (at tibia and radius), trabecular number (Tb.N), trabecular bone volume fraction (BV/TV) (at tibia), and trabecular thickness (Tb.Th) (at radius). Denosumab improved tibial trabecular vBMD and Tb.N. Zoledronate improved only tibial total vBMD. Microfinite element analysis-derived strength parameters were unchanged, except for a modest increase in tibial stiffness with denosumab. BTMs decreased with antiresorptives, increased with teriparatide, and showed an anabolic window by 6 weeks. CONCLUSION: Teriparatide demonstrated early improvements in bone microarchitecture in postmenopausal women with T2D while denosumab showed a modest increase in bone stiffness at the distal tibia. Larger, adequately powered studies are needed to clarify the relative effects of anabolic and antiresorptive therapies in this population.
引用
- Prasad TN, Pal R, Bhadada SK, et al. Interim Effects of Zoledronate, Denosumab, or Teriparatide on Bone Microarchitecture in Type 2 Diabetes: A Pilot Trial. J Clin Endocrinol Metab. 2026. PMID: 41183496. doi:10.1210/clinem/dgaf589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。